Gender (male/female), n |
43/8 |
AGE (years) |
46.4±12.8 (47,15-89) |
Weight (kg) |
60.0 ±13.1 (58,36-99) |
PLT count (109/L) |
85.4±70.8
(65,20-450) |
ALT (U/L) |
59.4±70.7 (39.5,5.7-48.6) |
AST (U/L) |
106.5±98.5 (78.3,15.5-737) |
ALB (g/L) |
32.6±4.9 (32.4,23.3-49.3) |
TBIL (μmol/L) |
300.6±178.4
(314,7.8-729) |
DBIL (μmol/L) |
205.1±124.0 (217.4,3.4-545.2) |
BUN (mmol/L) |
7.3±5.8 (5.4,1.3-33.7) |
CLcr (mL/min)b
|
100.6±45.1
(94.5,17.3-231) |
INR |
2.38±1.2 (2.1,0.9-5.9) |
PT (second) |
25.6±9.9 (23.2,11.8-53.9) |
PTA (%) |
42.9±24.0 (35,13-117) |
Ctrough (mg/L) |
3.9±2.5 (3.4,0.06-14.08) |
Concomitant medication (PPI) |
n (%) of patients |
Omeprazole |
8 (15.7%) |
Esomeprazole |
9 (17.6%) |
Pantoprazole |
6 (11.8%) |
Lansoprazole |
16 (31.4%) |
Genotype distribution frequency |
|
Ultrarapid metabolizer (UM) |
1 (2.0%) |
Extensive metabolizer (EM) |
24 (47.1%) |
Intermediate metabolizer (IM) |
21 (41.1%) |
Poor metabolizer(PM)
Child-Pugh class (A:B:C)
MELD score
|
5 (9.8%)
4:11:36
22.4±10.7(23.8,1-45.5)
|